PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
15781395-3	2005	Furthermore, most of the inhibitors enhanced the antibacterial activities of piperacillin (PIP) and ceftazidime (CAZ) particularly against TEM-1 and CTX-1 producing bacterial strains.	Ceftazidime	100-111	hypothetical protein	Escherichia coli	139-144	
28812563-3	2016	The plasmid accelerated resistance evolution by increasing the rate of appearance of novel TEM-1 mutations, thereby conferring resistance to ceftazidime, and then by amplifying the effect of TEM-1 mutations due to the increased gene dosage.	Ceftazidime	141-152	hypothetical protein	Escherichia coli	91-96	
17434819-0	2007	In vitro selection and characterization of mutants in TEM-1-producing Escherichia coli by ceftazidime and ceftibuten.	Ceftazidime	90-101	hypothetical protein	Escherichia coli	54-59	
17434819-1	2007	The present work was undertaken to study the ability of ceftazidime and ceftibuten to selectin vitro Escherichia coli HB101 harboring bla(TEM-1) beta-lactamase gene.	Ceftazidime	56-67	hypothetical protein	Escherichia coli	138-143	
15781395-3	2005	Furthermore, most of the inhibitors enhanced the antibacterial activities of piperacillin (PIP) and ceftazidime (CAZ) particularly against TEM-1 and CTX-1 producing bacterial strains.	Ceftazidime	113-116	hypothetical protein	Escherichia coli	139-144	
9174192-9	1997	In addition, the MIC of ceftazidime for E. coli transconjugant GR202 (1 microg/ml) was lower than that for E. coli TEM-15 (16 microg/ml) and higher than that for E. coli IRT-4 or TEM-1 (0.06 microg/ml).	Ceftazidime	24-35	hypothetical protein	Escherichia coli	115-120	
15504890-0	2004	Pharmacodynamics of ceftazidime plus the serine beta-lactamase inhibitor AM-112 against Escherichia coli containing TEM-1 and CTX-M-1 beta-lactamases.	Ceftazidime	20-31	hypothetical protein	Escherichia coli	116-121	
15504890-1	2004	A strain of Escherichia coli containing TEM-1 and CTX-M-1 was tested in an in vitro pharmacokinetic model against ceftazidime with and without AM-112, a serine beta-lactamase inhibitor.	Ceftazidime	114-125	hypothetical protein	Escherichia coli	40-45	
10898697-3	2000	All variants obtained by submitting an Escherichia coli strain that contains a bla(TEM-1) gene to fluctuating challenge with both ceftazidime and amoxicillin contained only mutations previously detected in naturally occurring beta-lactamases.	Ceftazidime	130-141	hypothetical protein	Escherichia coli	83-88	
8067751-5	1994	The doubly mutated derivative of the TEM-1 enzyme (Ser-164/Ser-244) retains the characteristics of the Ser-164 mutant enzyme, i.e., enhanced activity against ceftazidime and sensitivity to inactivation by clavulanate.	Ceftazidime	158-169	hypothetical protein	Escherichia coli	37-42	
2692515-4	1989	The beta-lactamase efficiently hydrolyzed cefotaxime and ceftriaxone but only moderately hydrolyzed ceftazidime and was inhibited by clavulanate and sulbactam (1 microM) and by anti-TEM-1 and anti-TEM-2 sera.	Ceftazidime	100-111	hypothetical protein	Escherichia coli	182-187	
32196336-3	2020	Compounds 2-6 in combinations with ceftazidime and ampicillin were also efficient in restoring antibiotic efficacy in E. coli strains carrying class C (CMY-2 and DHA-1) and class A (TEM-1 and CTX-M-2) beta-lactamase enzymes, respectively.	Ceftazidime	35-46	hypothetical protein	Escherichia coli	182-187